Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies

OBJECTIVE: To evaluate onset of effect of galcanezumab in patients with episodic migraine. BACKGROUND: Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related peptide and is indicated for preventive treatment of migraine. DESIGN/METHODS: Data on the primary outcome measure were a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Headache
Glavni autori: Detke, Holland C., Millen, Brian A., Zhang, Qi, Samaan, Karen, Ailani, Jessica, Dodick, David W., Aurora, Sheena K.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Research Submissions
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7028148/
https://ncbi.nlm.nih.gov/pubmed/31710104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13691
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items